Literature DB >> 22833965

Viral vectors and delivery strategies for CNS gene therapy.

Steven J Gray1, Kenton T Woodard, R Jude Samulski.   

Abstract

This review aims to provide a broad overview of the targets, challenges and potential for gene therapy in the CNS, citing specific examples. There are a broad range of therapeutic targets, with very different requirements for a suitable viral vector. By utilizing different vector tropisms, novel routes of administration and engineered promoter control, transgenes can be targeted to specific therapeutic applications. Viral vectors have proven efficacious in preclinical models for several disease applications, spurring several clinical trials. While the field has pushed the limits of existing adeno-associated virus-based vectors, a next generation of vectors based on rational engineering of viral capsids should expand the application of gene therapy to be more effective in specific therapeutic applications.

Entities:  

Mesh:

Year:  2010        PMID: 22833965      PMCID: PMC4509525          DOI: 10.4155/tde.10.50

Source DB:  PubMed          Journal:  Ther Deliv        ISSN: 2041-5990


  129 in total

1.  Transduction characteristics of adeno-associated virus vectors expressing cap serotypes 7, 8, 9, and Rh10 in the mouse brain.

Authors:  Cassia N Cearley; John H Wolfe
Journal:  Mol Ther       Date:  2006-01-18       Impact factor: 11.454

2.  Gene transfer of human acid sphingomyelinase corrects neuropathology and motor deficits in a mouse model of Niemann-Pick type A disease.

Authors:  James C Dodge; Jennifer Clarke; Antonius Song; Jie Bu; Wendy Yang; Tatyana V Taksir; Denise Griffiths; Michael A Zhao; Edward H Schuchman; Seng H Cheng; Catherine R O'Riordan; Lamya S Shihabuddin; Marco A Passini; Gregory R Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2005-11-21       Impact factor: 11.205

3.  Lentiviral-mediated silencing of SOD1 through RNA interference retards disease onset and progression in a mouse model of ALS.

Authors:  Cédric Raoul; Toufik Abbas-Terki; Jean-Charles Bensadoun; Sandrine Guillot; Georg Haase; Jolanta Szulc; Christopher E Henderson; Patrick Aebischer
Journal:  Nat Med       Date:  2005-03-13       Impact factor: 53.440

4.  Enhanced survival of the LINCL mouse following CLN2 gene transfer using the rh.10 rhesus macaque-derived adeno-associated virus vector.

Authors:  Dolan Sondhi; Neil R Hackett; Daniel A Peterson; Jamie Stratton; Michael Baad; Kelly M Travis; James M Wilson; Ronald G Crystal
Journal:  Mol Ther       Date:  2006-12-19       Impact factor: 11.454

5.  Engineering cell lines for production of replication defective HSV-1 gene therapy vectors.

Authors:  Kyle G Grant; David M Krisky; Mohammed M Ataai; Joseph C Glorioso
Journal:  Biotechnol Bioeng       Date:  2009-03-01       Impact factor: 4.530

6.  Safety and tolerability of putaminal AADC gene therapy for Parkinson disease.

Authors:  C W Christine; P A Starr; P S Larson; J L Eberling; W J Jagust; R A Hawkins; H F VanBrocklin; J F Wright; K S Bankiewicz; M J Aminoff
Journal:  Neurology       Date:  2009-10-14       Impact factor: 9.910

7.  Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile batten disease.

Authors:  Mario A Cabrera-Salazar; Eric M Roskelley; Jie Bu; Bradley L Hodges; Nelson Yew; James C Dodge; Lamya S Shihabuddin; Istvan Sohar; David E Sleat; Ronald K Scheule; Beverly L Davidson; Seng H Cheng; Peter Lobel; Marco A Passini
Journal:  Mol Ther       Date:  2007-07-17       Impact factor: 11.454

8.  Intramuscular injection of AAV-GDNF results in sustained expression of transgenic GDNF, and its delivery to spinal motoneurons by retrograde transport.

Authors:  Yan-Yan Lu; Li-Jun Wang; Shin-ichi Muramatsu; Kunihiko Ikeguchi; Ken-ichi Fujimoto; Takashi Okada; Hiroaki Mizukami; Takashi Matsushita; Yutaka Hanazono; Akihiro Kume; Toshiharu Nagatsu; Keiya Ozawa; Imaharu Nakano
Journal:  Neurosci Res       Date:  2003-01       Impact factor: 3.304

9.  VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model.

Authors:  Mimoun Azzouz; G Scott Ralph; Erik Storkebaum; Lucy E Walmsley; Kyriacos A Mitrophanous; Susan M Kingsman; Peter Carmeliet; Nicholas D Mazarakis
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration.

Authors:  Francesca Simonelli; Albert M Maguire; Francesco Testa; Eric A Pierce; Federico Mingozzi; Jeannette L Bennicelli; Settimio Rossi; Kathleen Marshall; Sandro Banfi; Enrico M Surace; Junwei Sun; T Michael Redmond; Xiaosong Zhu; Kenneth S Shindler; Gui-Shuang Ying; Carmela Ziviello; Carmela Acerra; J Fraser Wright; Jennifer Wellman McDonnell; Katherine A High; Jean Bennett; Alberto Auricchio
Journal:  Mol Ther       Date:  2009-12-01       Impact factor: 11.454

View more
  35 in total

Review 1.  Targeting epigenetic mechanisms for chronic visceral pain: A valid approach for the development of novel therapeutics.

Authors:  Tijs Louwies; Casey O Ligon; Anthony C Johnson; Beverley Greenwood-Van Meerveld
Journal:  Neurogastroenterol Motil       Date:  2018-11-04       Impact factor: 3.598

Review 2.  Viral vectors for gene delivery to the central nervous system.

Authors:  Thomas B Lentz; Steven J Gray; R Jude Samulski
Journal:  Neurobiol Dis       Date:  2011-10-07       Impact factor: 5.996

Review 3.  Current prospects and challenges for epilepsy gene therapy.

Authors:  Marc S Weinberg; Thomas J McCown
Journal:  Exp Neurol       Date:  2011-10-08       Impact factor: 5.330

4.  Preclinical differences of intravascular AAV9 delivery to neurons and glia: a comparative study of adult mice and nonhuman primates.

Authors:  Steven J Gray; Valerie Matagne; Lavanya Bachaboina; Swati Yadav; Sergio R Ojeda; R Jude Samulski
Journal:  Mol Ther       Date:  2011-04-12       Impact factor: 11.454

Review 5.  Methods for gene transfer to the central nervous system.

Authors:  Boris Kantor; Rachel M Bailey; Keon Wimberly; Sahana N Kalburgi; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 6.  Current status of non-viral gene therapy for CNS disorders.

Authors:  Rahul Dev Jayant; Daniela Sosa; Ajeet Kaushik; Venkata Atluri; Arti Vashist; Asahi Tomitaka; Madhavan Nair
Journal:  Expert Opin Drug Deliv       Date:  2016-06-01       Impact factor: 6.648

Review 7.  Passive Immunotherapies for Central Nervous System Disorders: Current Delivery Challenges and New Approaches.

Authors:  Niyanta N Kumar; Michelle E Pizzo; Geetika Nehra; Brynna Wilken-Resman; Sam Boroumand; Robert G Thorne
Journal:  Bioconjug Chem       Date:  2018-10-24       Impact factor: 4.774

Review 8.  Clinical applications involving CNS gene transfer.

Authors:  Boris Kantor; Thomas McCown; Paola Leone; Steven J Gray
Journal:  Adv Genet       Date:  2014       Impact factor: 1.944

Review 9.  Live-Animal Epigenome Editing: Convergence of Novel Techniques.

Authors:  J Antonio Gomez; Ulrika Beitnere; David J Segal
Journal:  Trends Genet       Date:  2019-05-22       Impact factor: 11.639

Review 10.  Recent gene therapy advancements for neurological diseases.

Authors:  Sahana Nagabhushan Kalburgi; Nadia N Khan; Steven J Gray
Journal:  Discov Med       Date:  2013-02       Impact factor: 2.970

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.